PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193424
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193424
The Next-Generation Biomanufacturing Market size was valued at USD 20,807.3 Million in 2022, expanding at a CAGR of 10.2% from 2023 to 2030.
The development and production of a wide range of products with the highest level of quality possible than the first generation of biomanufacturing products is made possible by next-generation biomanufacturing services. In order to improve process flexibility and efficiency, these services concentrate on single-use technologies including single-use bioreactors and single-use biocontainers.
Market Dynamics
The development of the next-generation biomanufacturing market is anticipated to be aided by the expansion of the global biopharmaceutical industry, increased commercialization, pipeline development, adoption of cutting-edge technology, and novel innovations in design, performance, efficiency, and other areas. On the other hand, the possibility that the next-generation biomanufacturing industry will expand over the projection period will increase as a result of the funding that the public and private organizations are making available for the development of novel technologies. Moreover, Growing environmental concerns, pollution levels, water scarcity, and seamless services in the pharmaceutical industry will propel the global biomanufacturing market. The demand for market from facilities utilizing next-generation biomanufacturing will also rise. Additionally, the usage of single-use products will reduce costs, decrease product contamination, and boost flexibility, increasing demand for next-generation biomanufacturing. However, large capital investments, related uncertain expenses, a shortage of qualified specialists, operational complexity, and compatibility issues are a few of the factors that limit market expansion.
Segmentation Analysis:
Based on end user, the fastest growth is anticipated in the biopharmaceutical sector during the forecasted period. The biopharmaceutical company is experiencing a rapid digital change, opening up new potential for the development of biomanufacturing to address issues with producing and supplying biologic medications. Additionally, the rapidly expanding commercialization and adoption of novel biomanufacturing strategies are having a positive impact on the growth of the Next-Generation Biomanufacturing market globally. These strategies are designed to increase productivity and efficiency while lowering operating costs. Thus, driving the segmental growth over the forecast period.
Regional Analysis:
In 2022, North America dominated the global market for next-generation biomanufacturing. The development of the next-generation biomanufacturing market in North America is being significantly assisted by large, well-equipped biomanufacturing facilities with cutting-edge infrastructure and major expenditures in the biomanufacturing industry. Additionally, the rapidly growing biopharmaceuticals and biologics sector in North America holds out enormous potential for the sector's expansion, drawing the interest of potential investors. Thermo Fisher Scientific, Inc., GE Healthcare, PBS Biotech, CESCO Bioengineering Co. Ltd., and Meissner Filtration Products, Inc. are just a few of the major companies with U.S. headquarters who have helped the market in the region development.
Recent Development:
In February 2020, Honeywell International Inc. and Bigfinite, Inc. announced joint venture. This collaboration is aimed to contribute to process automation and controls technologies, utilising Bigfinite's AI, data analytics, and machine learning platform to assist the pharmaceutical and biotech sectors in accelerating therapeutic therapies.
In April 2020, Akron Biotech acquired Sarasota, Florida's Cambryn Biologics. Modern biomanufacturing equipment is used at the site.
Key features of the study:
This proposed research study on the Next-Generation Biomanufacturing market provides market size (US$ Million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains an attractive investment proposition matrix for the Next-Generation Biomanufacturing market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Next-Generation Biomanufacturing market
The impact of COVID-19 on the Next-Generation Biomanufacturing market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight into the Next-Generation Biomanufacturing market post-COVID will also be covered.
To give the users of this report a comprehensive view of the Next-Generation Biomanufacturing market, we have also included a competitive landscape and key innovator analysis for the Next-Generation Biomanufacturing market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand the financial information and strategic initiatives of players operating in the Next-Generation Biomanufacturing market.
In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launches, research & development, and regional expansion of major participants involved in the market on global as well as regional levels.
The global Next-Generation Biomanufacturing market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET KEY PLAYERS
Oxford Nanopore Technologies plc
Thermo Fischer Scientific Inc.
Illumina Inc.
Agilent Technologies, Inc.
PerkinElmer Inc.
BGI
QIAGEN
F. Hoffmann-La Roche Ltd
Eurofins Scientific
Takara Bio Inc.
GENEWIZ, Inc.
Hamilton Company
Macrogen Inc.
Tecan Trading AG
GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET, BY WORKFLOW TYPE
Upstream Biomanufacturing Workflow
Single-Use Upstream Biomanufaturing Workflow
Downstream Biomanufaturing Workflow
GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET, BY APPLICATION
Monoclonal Antibodies
Vaccines
Recombinant protein
Hormones
Others
GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET, BY END USER
Biopharmaceutical Companies
Research Institutions
Contract Research Organizations
GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA